Peroxisome proliferator activated receptor gamma and its activation in the treatment of insulin resistance and atherosclerosis: issues and opportunities

被引：12

作者：

Beckman, J

Raji, A

Plutzky, J

机构：

[1] Harvard Univ, Sch Med, Boston, MA 02115 USA

[2] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA

[3] Brigham & Womens Hosp, Div Endocrinol, Boston, MA 02115 USA

来源：

CURRENT OPINION IN CARDIOLOGY | 2003年 / 18卷 / 06期

关键词：

insulin resistance; atherosclerosis; thiazolidinedione; PPAR;

D O I：

10.1097/00001573-200311000-00009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Atherosclerosis remains a major complication of type 2 diabetes mellitus. Increasing data suggest insulin resistance, and its associated metabolic abnormalities, may underlie many of the cardiovascular complications seen among patients with insulin resistance and/or diabetes mellitus. This insight has also suggested that therapeutic approaches targeting insulin resistance may not only improve metabolism but also limit complications like atherosclerosis and the inflammation that contributes to it. Thiazolidinediones, agonists of the nuclear receptor peroxisome proliferator activated receptor gamma, are one such insulin-sensitizing therapeutic intervention in current use among patients with type 2 diabetes mellitus. The existing data regarding thiazolidinedione effects on the cardiovascular system are reviewed and considered, along with the future prospects for this emerging drug class.

引用

页码：479 / 485

页数：7

共 72 条

[1]

[Anonymous], 1998, Diabetes Care, V21, P179

[2]

[Anonymous], OXFORD TXB ENDOCRINO

[3] TRIPOD (TRoglitazone in the Prevention of Diabetes): A randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus [J].

Azen, SP ;

Peters, RK ;

Berkowitz, K ;

Kjos, S ;

Xiang, A ;

Buchanan, TA .

CONTROLLED CLINICAL TRIALS, 1998, 19 (02) :217-231

[4] Diabetes and atherosclerosis - Epidemiology, pathophysiology, and management [J].

Beckman, JA ;

Creager, MA ;

Libby, P .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (19) :2570-2581

[5] Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects [J].

Berger, J ;

Leibowitz, MD ;

Doebber, TW ;

Elbrecht, A ;

Zhang, B ;

Zhou, GC ;

Biswas, C ;

Cullinan, CA ;

Hayes, NS ;

Li, Y ;

Tanen, M ;

Ventre, J ;

Wu, MS ;

Berger, GD ;

Mosley, R ;

Marquis, R ;

Santini, C ;

Sahoo, SP ;

Tolman, RL ;

Smith, RG ;

Moller, DE .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (10) :6718-6725

[6]

Bliss M., 2000, The Discovery of Insulin

[7] Design and synthesis of 2-methyl-2-{4-[2-(5-methyl-2-aryloxazol-4-yl)ethoxy]phenoxy}propionic acids:: A new class of dual PPARα/γ agonists [J].

Brooks, DA ;

Etgen, GJ ;

Rito, CJ ;

Shuker, AJ ;

Dominianni, SJ ;

Warshawsky, AM ;

Ardecky, R ;

Paterniti, JR ;

Tyhonas, J ;

Karanewsky, DS ;

Kauffman, RF ;

Broderick, CL ;

Oldham, BA ;

Montrose-Rafizadeh, C ;

Winneroski, LL ;

Faul, MM ;

McCarthy, JR .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (13) :2061-2064

[8] Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women [J].

Buchanan, TA ;

Xiang, AH ;

Peters, RK ;

Kjos, SL ;

Marroquin, A ;

Goico, J ;

Ochoa, C ;

Tan, S ;

Berkowitz, K ;

Hodis, HN ;

Azen, SP .

DIABETES, 2002, 51 (09) :2796-2803

[9] The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: A placebo-controlled randomized clinical trial [J].

Caballero, AE ;

Saouaf, R ;

Lim, SC ;

Hamdy, O ;

Abou-Elenin, K ;

O'Connor, C ;

LoGerfo, FW ;

Horton, ES ;

Veves, A .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2003, 52 (02) :173-180

[10] Diabetes mellitus - A hypercoagulable state [J].

Carr, ME .

JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2001, 15 (01) :44-54

← 1 2 3 4 5 6 7 8 →